Neuralink's 26 Patients vs. Synchron's 15: The $9.7 Billion Brain Implant Race
Neuralink has 26 patients, $1.3B in funding and a $9.7B valuation, but Synchron's less invasive Stentrode may win FDA clearance first. China already has a commercial BCI.
By Grace Kim
5 min read

What's News
- Neuralink is valued at roughly $9.7 billion with $1.3 billion in funding and 26 implant patients.
- Synchron has implanted its Stentrode in 15 people and is 'neck and neck' with Neuralink in FDA review.
- China approved the world's first commercially available brain-computer interface in March.
- 194 countries signed a 2025 Unesco recommendation on neurotechnology ethics.
- OpenAI invested in Sam Altman's BCI startup Merge Labs in early 2026.
Elon Musk's Neuralink is valued at roughly $9.7 billion and has $1.3 billion in funding — more than double any rival brain-implant company — yet it may still lose the U.S. race to market. Synchron, a competitor whose device requires no craniotomy, is "neck and neck" in the FDA approval process, and the winner will open a market that touches everything from medical devices to the privacy of human thought.
By Grace Kim
Roughly 26 people, all with severe disabilities, currently use Neuralink's N1 implant in testing. A robotic arm drills a circle into the skull and places a quarter-size device on brain tissue, trailing 64 wires thinner than a human hair. Electrodes pick up neural signals, and the implant transmits them to a phone or tablet — letting patients text, post on social media, and play video games without lifting a finger.
Who's racing whom?
No brain implant is on the U.S. market yet. Alongside Neuralink, the field includes Paradromics (restoring speech), Precision Neuroscience (paralysis patients), and Neuvotion, whose commercially available AI-guided wearable helps restore movement in stroke and spinal cord injury patients.
"It is definitely a race," says Chad Bouton, CEO of Neuvotion. "I think in the next three or four years we might see an FDA clearance."
Synchron founder and CEO Thomas Oxley, a neurosurgeon, told Fortune his company has implanted its Stentrode device in 15 people — five more since last year. Neuralink went from seven patients to 26 in the same period. "They're going fast," Oxley said of his rival.
Synchron, valued at nearly $1 billion in its latest round, was also the first to integrate with Apple's standardized Bluetooth-powered BCI connection in 2025. Its Stentrode goes in through a blood vessel via catheter, like a heart stent, in a two-hour surgery; a wire tunnels under the skin to a coin-size receiver in the chest. The trade-off: it's less powerful than the N1. Patients activate it by thinking "Move my foot," which an algorithm interprets as a select command.
Oxley says a more powerful device is coming "soon," aimed at mass-market adoption. It will access more parts of the brain and won't require a craniotomy. "Everyone in the field agrees that the holy grail of BCI is whole-brain sensing," he said, describing a future implant as a "cognitive copilot" for patients with aging-related cognitive decline or dementia. "I think that could be huge."
Neuralink, meanwhile, announced in June 2026 its first procedure without breaking the dura, the brain's protective layer. "I think that's a kind of technical tour de force, and it probably leads to a very powerful system," says Adam Marblestone, cofounder of Convergent Research and a former Google DeepMind scientist.
What does AI change?
The race predates ChatGPT's 2022 debut, but advancing AI stands to dramatically sharpen what implants can decipher. Matt Angle, CEO of Paradromics, says AI-enhanced BCIs could one day control humanoid robots or AI agents directly from thoughts. As research goes "cognitively upstream from language," he says, implants could know desires before we're aware of them — if you're hungry, "then the BCI would already understand what we're hungry for, and it would deduce the next reasonable thing," perhaps ordering food itself. "It won't be mainstream right away," he said, "but it'll come sooner than a lot of people are expecting."
OpenAI CEO Sam Altman, who wrote in a 2017 blog post that "our phones control us and tell us what to do and when," cofounded the BCI company Merge Labs in 2025; OpenAI invested in it in early 2026. A spokesperson expects product details in "a couple months."
For workers, the stakes include surveillance. A BCI connected to a work computer could record biological signals revealing focus — or mind-wandering — and employers could nudge people back to task if two-way communication develops, argues Duke University professor Nita Farahany, author of a book on defending freedom of thought.
"What you're thinking and feeling is your last space of true privacy. It's the most fundamental aspect of what it means to be human," Farahany says. "We are rapidly heading toward a world of brain transparency, in which scientists, doctors, governments, and companies may peer into our brains and minds at will. Companies [could] know what products we want before we do."
What do patients get today?
Neuralink's first patient, Noland Arbaugh, paralyzed after a diving accident, received his implant in January 2024. He has played Civilization and is writing a book with a partner writer; the implant enabled world travel for speaking engagements and a relationship. "Being paralyzed still sucks," he posted, but he's "constantly blown away" by the advances. "It has absolutely changed my outlook on life and what I'm able to accomplish and what I think I can do in the future," Arbaugh said in a 2025 interview. "So it has given me a lot of hope for myself."
Who's watching China?
China approved the world's first commercially available BCI in March. The industry there is "very fast, very active, and very dynamic," Oxley said. Asked if China's pace makes him nervous, he replied: "Yes." The stakes mirror semiconductor and EV supply-chain fights — but more extreme, since Chinese-made implant hardware could theoretically expose Americans' internal monologues.
Europe has about five BCI companies, including Spain's InBrain, targeting Parkinson's treatment. Science Corporation, led by Neuralink cofounder Max Hodak, won European approval for a vision-restoring device in July 2026 and implanted its first patient in October.
In 2025, Unesco published a neurotechnology ethics recommendation signed by 194 countries, calling development an "ethical imperative" while demanding safeguards for autonomy and mental privacy. Farahany, the U.S. State Department delegate to that effort, is now building a voluntary neurotechnology "trust index" to rate companies against ethical commitments.
"The concerns are profound and large," she says. "It's the ultimate merger. Where does the AI end, and where does the human begin, and vice versa?"
Source: fortune.com
More from Grace Kim
Show full bio
Market editor covering people, launches and day-to-day practice in entrepreneurship, startups and venture funding at Business Bearings.
2,582 articles